Liraglutide as additional treatment for type 1 diabetes

European Journal of Endocrinology

Volumn 165, Issue 1, 2011, Pages 77-84

  Varanasi, Ajay ^a   Bellini, Natalie ^a   Rawal, Deepti ^a   Vora, Mehul ^a   Makdissi, Antoine ^a   Dhindsa, Sandeep ^a   Chaudhuri, Ajay ^a   Dandona, Paresh ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN; C PEPTIDE;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DIET RESTRICTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG INDUCED HEADACHE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MALE; NAUSEA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; WEIGHT REDUCTION; METABOLISM; ADD ON THERAPY; DOSE RESPONSE; DRUG EFFICACY; HEADACHE; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; WEIGHT LOSS;

EID: 79959392262     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0330     Document Type: Article

References (24)

1. Banting FG & Best CH. Internal secretion of pancreas. Journal of Laboratory and Clinical Medicine 1922 7 464-480.
2. Hahr AJ & Molitch ME. Optimizing insulin therapy in patients with type 1 and type 2 diabetes mellitus: optimal dosing and timing in the outpatient setting. American Journal of Therapeutics 2008 15 543-550. (doi:10.1097/MJT. 0b013e31815aeb79)
3. Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer S, Wilson DM, Wolpert H, Wysocki T & Xing D. Continuous glucose monitoring and intensive treatment of type 1 diabetes. New England Journal of Medicine 2008 359 1464-1476. (doi:10.1056/NEJMoa0805017)
4. Fonseca VA, Zinman B, Nauck MA, Goldfine AB & Plutzky J. Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies. American Journal of Medicine 2010 123 S2-S10. (doi:10.1016/j.amjmed.2010.04.002)
5. Cervera A, Wajcberg E, Sriwijitkamol A, Fernandez M, Zuo P, Triplitt C, Musi N, DeFronzo RA & Cersosimo E. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. American Journal of Physiology. Endocrinology and Metabolism 2008 294 E846-E852. (doi:10.1152/ajpendo.00030.2008)
6. Baron AD, Schaeffer L, Shragg P & Kolterman OG. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 1987 36 274-283. (doi:10.2337/diabetes.36.3.274)
7. Gerich JE, Charles MA & Grodsky GM. Regulation of pancreatic insulin and glucagon secretion. Annual Review of Physiology 1976 38 353-388. (doi:10.1146/annurev.ph.38.030176.002033)
8. Abdul-Ghani M & DeFronzo RA. Fasting hyperglycemia impairs glucose but not insulin-mediated suppression of glucagon secretion. Journal of Clinical Endocrinology and Metabolism 2007 92 1778-1784. (doi:10.1210/jc.2006-1515)
9. Dupré J, Behme MT & McDonald TJ. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. Journal of Clinical Endocrinology and Metabolism 2004 89 3469-3473. (doi:10.1210/jc.2003-032001)
10. Raman VS, Mason KJ, Rodriguez LM, Hassan K, Yu X, Bomgaars L & Heptulla RA. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care 2010 33 1294-1296. (doi:10.2337/dc09-1959)
11. Lovshin JA & Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nature Reviews. Endocrinology 2009 5 262-269. (doi:10.1038/nrendo. 2009.48)
12. Kielgast U, Asmar M, Madsbad S & Holst JJ. Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients. Journal of Clinical Endocrinology and Metabolism 2010 95 2492-2496. (doi:10.1210/jc.2009-2440)
13. Brennand K & Melton D. Slow and steady is the key to beta-cell replication. Journal of Cellular and Molecular Medicine 2009 13 472-487. (doi:10.1111/j.1582-4934.2008.00635.x)
14. Meier JJ, Bhushan A, Butler AE, Rizza RA & Butler PC. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia 2005 48 2221-2228. (doi:10.1007/s00125- 005-1949-2)
15. Bosi E. Time for testing incretin therapies in early type 1 diabetes? Journal of Clinical Endocrinology and Metabolism 2010 95 2607-2609. (doi:10.1210/jc.2009-2741)
16. Rother KI, Spain LM, Wesley RA, Digon BJ III, Baron A, Chen K, Nelson P, Dosch HM, Palmer JP, Brooks-Worrell B, Ring M & Harlan DM. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care 2009 32 2251-2257. (doi:10.2337/dc09-0773)
17. Wajchenberg BL, Feitosa AC, Rassi N, Lerario AC & Betti RT. Glycemia and cardiovascular disease in type 1 diabetes mellitus. Endocrine Practice 2008 14 912-923.
18. Larkin ME, Backlund JY, Cleary P, Bayless M, Schaefer B, Canady J & Nathan DM. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabetic Medicine 2010 27 451-458. (doi:10.1111/j.1464-5491.2010.02972.x)
19. Luczyński W, Szypowska A, Głowińska-Olszewska B & Bossowski A. Overweight, obesity and features of metabolic syndrome in children with diabetes treated with insulin pump therapy. European Journal of Pediatrics 2010. (doi:10.1007/s00431-010-1372-7)
20. Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P & Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocrine Practice 2007 13 444-450.
21. Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG &Wintle ME. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clinical Therapeutics 2007 29 139-153. (doi:10.1016/j.clinthera.2007.01.015)
22. Okerson T, Yan P, Stonehouse A & Brodows R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. American Journal of Hypertension 2010 23 334-339. (doi:10.1038/ajh.2009.245)
23. Varanasi A, Chaudhuri A, Dhindsa S, Arora A, Lohano T, Vora M & Dandona P. Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, Crp and triglyceride concentrations. Endocrine Practice 2011 17 192-200. (doi:10.4158/EP10199.OR)
24. Montanya E & Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clinical Therapeutics 2009 31 2472-2488. (doi:10.1016/j.clinthera.2009.11.034)